⌕
Geron · GERN · Nasdaq
Tenet 55 · Mixed
Compare
$1.00+6.17%At closeTenet 55 · Mixed
$1.00+0.06 (+6.17%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Geron (GERN) Stock

Geron (GERN) closed at $1.00 on Nov 17, 2026; its Tenet Score is 55 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

21 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$1.00
Nov 17, 2026
Market cap
$606.8M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
0.84 – 2.01
low → high · as of close, Nov 16, 2026
Tenet Score
55/100
Mixed · 340 Healthcare peers

Industry: Drugs

Geron Corp. scores 55/100. Mixed. Strongest on value, quality is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
55/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
70
Quality
34
Health
60
Growth
58

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityDHealthCGrowthCMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.7×
Sep 30, 2026 balance sheet
P/S
2.8×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
−20%
TTM through Sep 30, 2026
Operating margin
−37.3%
fiscal 2025, before interest and tax
Net margin
−22.0%
TTM through Sep 30, 2026
Current ratio
6.31
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Geron Corp.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, whi…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 48 US ETFs · top wrappers by weightSee all ETFs holding GERN →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Geron in?

Geron is in the Healthcare sector and the Drugs industry.

What is Geron's Tenet Score?

Geron's Tenet Score is 55 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.